【摘要】 目的检测急性白血病(AL)患者血清中可溶性Fas(sFas)和可溶性ICAM-1(sI-CAM-1)水平,探讨sFas与sICAM-1水平的改变与化疗的相关性。方法采用酶联免疫吸附实验检测58例急性白血病患者化疗前后血清sFas与sICAM-1的水平。结果化疗前AL患者血清sFas与sICAM-1水平均高于正常对照组;化疗后获得骨髓缓解的AL患者血清sFas与sICAM-1的水平显著低于化疗前,但未获缓解者血清sFas与sICAM-1的水平与化疗前无差异;不论是化疗前还是化疗后、获得缓解或未获得缓解的AL患者血清sFas水平与sICAM-1的水平呈正相关。结论AL患者血清sFas与sICAM-1水平升高是白血病细胞逃避机体免疫攻击的重要机制;其分泌水平的升高或降低与白血病细胞对化疗药物是敏感或耐受相关,也可能与化疗药物通过一种或多种机制作用于FasL/Fas或(和)ICAM-1/LFA-1信号途径相关。更多还原

【Abstract】 Objective To detect the levels of soluble Fas (sFas) and soluble ICAM-1(sICAM-1) in the patients with acute leukemia(AL) and to explore the correlation of sFas and sICAM-1 with chemotherapy.Methods The concentrations of sFas and sICAM-1 in the sera of AL patients before or after chemotherapy were detected by ELISA.Results The levels of sFas and sICAM-1 in AL patients before chemotherapy were higher that in normal controls.After chemotherapy,the levels of sFas and sICAM-1 in AL patients achieving bone marrow remission(BMR) were remarkably decreased,which were close to the levels in normal subjects.The levels of sFas and sICAM-1 in AL patients after chemotherapy achieving no BMR were similar to those before chemotherapy.The level of sFas was positively associated with that of sICAM-1 in AL patients whatever chemotherapy was given and whatever BMR was reached after chemotherapy.Conclusion The levels of sFas and sICAM-1 were increased in the patients with AL,which may be correlated with the immune escape of leukemia.The changes of level of sFas and sICAM-1 in AL patients were associated with the response to chemotherapy,which was correlated with the FasL/Fas and/or ICAM-1/LFA-1 signal transduction pathways regulated by anticancer drugs via one or more related mechanisms.更多还原